查詢結果分析
來源資料
相關文獻
- Comparison of Oral Controlled-Release Morphine with Transdermal Fentanyl in Terminal Cancer Pain
- Relief of Cancer-related Oral Pain with Transdermal Fentany1 Patch
- The Analgesic Effect of PCA Buprenorphine in Taiwan's Gynecologic Patients
- The Efficacy of Intrathecal Coadministration of Morphine and Bupivacaine for Labor Analgesia
- 口服嗎啡在慢性癌症疼痛治療之應用
- Intrathecal Drug Delivery System with Programmable Morphine Pump for Pain of Terminally Ill Cancer Patients
- Comparison of PCA Nalbuphine and Morphine in Chinese Gynecologic Patients
- Epidural Morphine for Cancer Pain Control--Mangement of Pain With Implantable Portal System
- 腰部交感神經切除合併截趾手術對下肢缺血壞死性疼痛的治療經驗病例報告
- Comparison of Inguinal Nerve Block and Intravenous Fentanyl in Relieving Postinguinal Herniorrhaphy Pain for Pediatric Outpatients
頁籤選單縮合
題 名 | Comparison of Oral Controlled-Release Morphine with Transdermal Fentanyl in Terminal Cancer Pain=口服長效嗎啡及經皮膚吸收Fentanyl貼片於末期癌病疼痛治療之比較 |
---|---|
作 者 | 黃安年; 邱智鈴; 曹朝榮; 張傳林; | 書刊名 | 麻醉學雜誌 |
卷 期 | 35:1 1997.03[民86.03] |
頁 次 | 頁25-32 |
分類號 | 416.5 |
關鍵詞 | 麻醉劑; 麻醉止痛劑; 嗎啡; 控制釋出; 給予; 口服; 經皮膚; 疾病; 末期癌症; 疼痛; Anesthetics; narcotics:morphine; Controlled-release, fentanyl; Administration: oral, transdermal; Disease: cancer, teminal; Pain; |
語 文 | 英文(English) |
中文摘要 | 背景:根據過去對癌病疼痛治療之研究得知,每天服用兩次之長效型嗎啡比傳統 短效型嗎啡來得簡單方便。而最近發展出來的經皮 fentanyl 貼片,是一種可以達到相同止 痛的的新途徑。本研究主要目的在比較酚它尼疼痛貼片與長效型嗎啡在慢性癌病疼痛治療上 之止痛效果、安全性及副作用。 方法:在此開放、比較及隨機之研究中,所有病人在進入穩定期均給予口服短效型嗎啡,待 穩定後則換算為長效型嗎啡或 fentanyl 疼痛貼片並進入十四天的治療期。而口服短效型嗎 啡則用作治療期中之中間痛備用藥物。本研究並於穩定期前後及治療期中作治療效果之評估 ,其項目包括:疼痛程度、頻率、改善程度、情緒狀況、睡眠品質、活動情形及副作用等。 結果:在 47 位末期癌症病人中,有 40 位完成本研究,兩組各有 20 位病人。結果顯示, 在治療前後除活動情形外,疼痛程度、頻率、睡眠品質等均有明顯之改善 (p<0.05)。 且除 了在長效型嗎啡組有 6 位及疼痛貼片組有 5 位出現明顯之嗜睡情況出現外 (p<0.05) 並沒 有特別之其他副作用。 相反地,在治療前已有之失眠情況有明顯之改善 (p<0.05)。兩組之 間在止痛效果及副作用中,並沒有明顯之差異。 結論:本研究結果證實, fentanyl 疼痛貼片與長效型嗎啡在慢性癌病疼痛之治療上,有著 相同的安全性及止痛效果。 fentanyl 貼片對於一些有嚴重嘔吐及吞嚥困難之病人,不失為 一個簡單且方便之方法。 |
英文摘要 | Background: Controlled-release morphine (MST) given twice daily provides a simpler and more convenient treatment regimen than 4-hourly opioid administration for the conrol of cancer pain. Recently, a new formulation of transdermal fentanyl(TDF) has been developed which provides a new route for the treatment of cancer pain. The present study was designed to compare the analgesic efficacy, safety and adverse effects of MST and TDF in the management of chronic cancer pain. Methods: In this open, comparative and randomized study,patienets were treated with oral morphine hydrochloride immediate-release (MHIR) in the stabilization phase and then the prescription was switched to MST of TDF for 14 days in the treatment phase. Oral MHIR was provided as rescue medication for breakthrough pain. Assessments of the pain intensity, pain frequency, degree of pain improvement profile of mood states, quality of sleep, activity status and adverse effects were performed before and after the stabilization phase and before and after the treatment phase. Results: Forty of 47 camcer patients completed the study with 20 patients in each group. There were significant (p<0.05) improvements in pain intensity, pain frequency, mood states and quality of sleep in both groups before and after treatment, while improvement in the activity status was not significant. No specific adverse effects were encountered except for drowsiness which occurred in 6 patients treated with MST and 5 treated with TDF (p<0.05). Insomnia was significantly improved (p<0.05) with both regimens compared with that in the period before treatment. There were no significant differences between the two study groups in analgesic efficacy or adverse effects. Conclusions: These results suggest that TDF and MST are safe and effective analgesics for the management of chronic cancer pain. However, TDF provides a simpler and more convenient treatment route for those patients with severe nausea, vomiting or dysphagia. |
本系統中英文摘要資訊取自各篇刊載內容。